Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Vlado Perkovic; Rajiv Agarwal; Paola Fioretto; Brenda R Hemmelgarn; Adeera Levin; Merlin C Thomas; Christoph Wanner; Bertram L Kasiske; David C Wheeler; Per-Henrik Groop; Conference Participants

doi:10.1016/j.kint.2016.09.010

Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Kidney Int. 2016 Dec;90(6):1175-1183. doi: 10.1016/j.kint.2016.09.010.

Authors

Collaborators

Conference Participants:
George L Bakris, Mark E Cooper, Dong-Wan Chae, Michael H Davidson, Ian H de Boer, Dick de Zeeuw, Alessia Fornoni, Luigi Gnudi, Charles A Herzog, Adriana M Hung, Tazeen Hasan Jafar, Meg Jardine, Vivekanand Jha, Linong Ji, Steven E Kahn, Robyn G Langham, Edgar V Lerma, Ronald C W Ma, Hirofumi Makino, Michel Marre, Michael Mauer, Kaj Metsärinne, Robert G Nelson, Roberto Pecoits-Filho, Carol A Pollock, Mohan Rajapurkar, Peter Rossing, Ivan Rychlík, Kumar Sharma, Robert C Stanton, Vladimír Tesař, Ilkka Tikkanen, Charlie R V Tomson, Robert D Toto, Yusuke Tsukamoto, Katherine R Tuttle, Takashi Wada, Winfred W Williams, Hong Zhang, Sophia Zoungas

Affiliations

¹ George Institute for Global Health, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, New South Wales, Australia. Electronic address: vperkovic@georgeinstitute.org.au.
² Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana, USA.
³ Department of Medicine, University of Padova, Italy.
⁴ Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Interdisciplinary Chronic Disease Collaboration, Calgary, Alberta, Canada; Libin Cardiovascular Institute and Institute of Public Health, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
⁵ Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Provincial Renal Agency, Vancouver, British Columbia, Canada; Centre for Health Evaluation and Outcomes Research, St. Paul's Hospital, Vancouver, British Columbia, Canada.
⁶ Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia.
⁷ Renal Division, University Hospital of Würzburg, Würzburg, Germany.
⁸ Division of Nephrology, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
⁹ University College London, London, UK.
¹⁰ Diabetic Complications Division, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland; Diabetes and Obesity Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland; Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Electronic address: per-henrik.groop@helsinki.fi.

PMID: 27884312
DOI: 10.1016/j.kint.2016.09.010

Abstract

The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.

Keywords: antidiabetic agents; cardiovascular disease; chronic kidney disease; diabetes; glycemic control; renoprotection.

Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Authors

Collaborators

Affiliations

Abstract

Publication types

MeSH terms

Grants and funding